Julieth Daniela Buell Acosta

Dr. Julieth Daniela Buell Acosta

Universidad Nacional de Colombia, Bogotá, Colombia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Julieth Daniela Buell AcostaJulieth Daniela Buell Acosta
Julieth Daniela Buell Acosta
MGMaria Garces
Maria Garces
APArturo José Parada-Baños
Arturo José Parada-Baños
EAEdith Angel-Muller
Edith Angel-Muller
MPMaria Paez-Leal
Maria Paez-Leal
JCJorge Caminos
Jorge Caminos
(1) Background: Fibroblast growth factor 21 (FGF-21) is an endocrine factor involved in glucose and lipid metabolism that exerts pleiotropic effects. The aim of this study was to investigate the serum FGF-21 profile in healthy and mild preeclamptic pregnant women at each trimester of pregnancy; (2) Methods: Serum FGF-21 levels were determined by ELISA in a nested case-control study within a longitudinal cohort study that included healthy (n = 54) and mild preeclamptic (n = 20) pregnant women, women at three months after delivery (n = 20) and eumenorrheic women during the menstrual cycle (n = 20); (3) Results: FGF-21 levels were significantly lower in the mid-luteal phase compared to the early follicular phase of the menstrual cycle in eumenorrheic women (p < 0.01). Maternal levels of FGF-21 were significantly lower in the first and second trimesters and peaked during the third trimester in healthy pregnant women (p < 0.01). Serum levels of FGF-21 in healthy pregnant were significantly lower in the first and second trimester of pregnancy compared with the follicular phase of the menstrual cycle and postpartum (p < 0.01). Serum FGF-21 levels were significantly higher in preeclamptic compared to healthy pregnant women during pregnancy (p < 0.01); (4) Conclusions: These results suggest that a peak of FGF-21 towards the end of pregnancy in healthy pregnancy and higher levels in preeclamptic women might play a critical role that contributes to protecting against the negatives effects of high concentrations of non-esterified fatty acids (NEFA) and hypertensive disorder. Furthermore, FGF-21 might play an important role in reproductive function in healthy eumenorrheic women during the menstrual cycle.

Verified
Journal Article
Open access
PDF file
MGMaria Garces
Maria Garces
Julieth Daniela Buell AcostaJulieth Daniela Buell Acosta
Julieth Daniela Buell Acosta
EÁEdith Ángel-Müller
Edith Ángel-Müller
APArturo José Parada-Baños
Arturo José Parada-Baños
JAJaidy Acosta-Alvarez
Jaidy Acosta-Alvarez
JCJorge Caminos
Jorge Caminos
The Liver-Expressed Antimicrobial Peptide 2 (LEAP-2) has emerged as an endogenous GHS-R antagonist and blunts the orexigenic action of ghrelin. This study aimed to determine the Ghrelin/LEAP-2 ratio in humans and rats during pregnancy. In humans, we conducted a nested case-control study within an observational prospective cohort. Healthy and mild preeclamptic pregnant women were studied at each trimester of gestation and three months postpartum. In addition, a group of non-pregnant women was studied into the follicular and luteal phases of the menstrual cycle. Furthermore, Ghrelin/LEAP-2 ratio was investigated in non-pregnant rats and at different periods of rat pregnancy. Human and rat serum ghrelin and LEAP-2 levels were determined using the commercially available ELISA kits. The Ghrelin/LEAP-2 ratio peak around the second trimester of gestation in healthy pregnant women (p < 0.05). Additionally, there were no statistically significant differences in Ghrelin/LEAP-2 ratio between healthy and preeclamptic pregnant women at each trimester of gestation (p > 0.05). The Ghrelin/LEAP-2 ratio in pregnant rat reached the peak around mid-gestation with a similar pattern to the human pregnancy. LEAP-2 was visualized by immunohistochemistry in human term placenta and rat placentas on days 12, 16 and 21 of pregnancy. In conclusion, this study provides the first evidence of a Ghrelin/LEAP-2 ratio peak around the half-way point of pregnancy onwards during human and rat pregnancy, and it might be associated with increased rates of weight gain during pregnancy. Thus, this study suggests that LEAP-2 and Ghrelin/LEAP-2 ratio might play an important role in maternal physiology adaptation of weight gain during pregnancy.

3 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMaria Fernanda Garcés
Maria Fernanda Garcés
Julieth Daniela Buell AcostaJulieth Daniela Buell Acosta
Julieth Daniela Buell Acosta
HRHaiver Antonio Rodríguez-Navarro
Haiver Antonio Rodríguez-Navarro
EPEstefania Pulido-Sánchez
Estefania Pulido-Sánchez
JRJuan José Rincon-Ramírez
Juan José Rincon-Ramírez
JCJorge Caminos
Jorge Caminos
This study aimed to determine ANGPTL3 serum levels in healthy young lean and obese non-diabetic men during an oral glucose tolerance test (OGTT) and correlate them with anthropometric, biochemical and hormonal parameters. A case–control study was carried out and 30 young obese non-diabetic (23.90 ± 3.84 years and BMI 37.92 ± 4.85 kg/m2) and 28 age-matched healthy lean (24.56 ± 3.50 years and BMI of 22.10 ± 1.72 kg/m2) men were included in this study. The primary outcome measures were serum basal ANGPTL3 and ANGPTL3–area under the curve (AUC) levels. The percentage of body fat was measured by dual-energy X-ray absorptiometry and biochemical, hormonal and insulin resistance indices were determined. Basal ANGPTL3 and ANGPTL3–AUC levels were significantly elevated (p < 0.05) in young obese subjects compared with lean subjects and were positively and significantly associated with different anthropometric measurements. Fasting ANGPTL3 serum levels were positively correlated with fasting insulin, leptin, Leptin/Adiponectin index and triglyceride—glucose index. Moreover, ANGPTL3–AUC was negatively correlated with Matsuda index. In this regard, chronically high ANGPTL3 levels in young obese subjects might favor triglyceride-rich lipoprotein clearance to replenish triglyceride stores by white adipose tissue rather than oxidative tissues.

13 April 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
MGMaría Fernanda Garces
María Fernanda Garces
HNHaiver Antonio Rodriguez - Navarro
Haiver Antonio Rodriguez - Navarro
Julieth Daniela Buell AcostaJulieth Daniela Buell Acosta
Julieth Daniela Buell Acosta
ACAlvaro Javier Burgos - Cardenas
Alvaro Javier Burgos - Cardenas
RVRoberto Franco - Vega
Roberto Franco - Vega
JCJorge Caminos
Jorge Caminos
Objective: Angiopoietin-like protein 3(ANGPTL3) is an important regulator of lipoprotein metabolism in the fed state by inhibiting the enzyme lipoprotein lipase in oxidative tissues. However, the possible role of ANGPTL3 throughout gestation and its relationship with hormonal and biochemical variables are still unknown. The aim of this study was to determinate serum ANGPTL3 level in healthy non-pregnant women, during healthy and preeclamptic pregnancy and postpartum.Methods: Serum ANGPTL3 was analyzed by enzyme-linked immunosorbent assay (ELISA), in a prospective cohort of healthy pregnant women (n = 52) and women with mild preeclampsia (n = 21), and women at three months postpartum (n = 20) and healthy non-pregnant women (n = 20). The results obtained were correlated with biochemical, hormonal and anthropometric variables and insulin resistance indices.Results: Levels of ANGPTL3 were not different between the follicular and the luteal phases of the cycle in healthy non-pregnant women. There was a significant reduction in serum ANGPTL3 levels from the first to the third trimester in healthy pregnant women compared with healthy non-pregnant and postpartum women (p 0.05)Conclusions: We describe for the first time the profile of ANGPTL3 throughout pregnancy and postpartum as well as and discussed about explore their potential contribution interactions with lipoprotein metabolism throughout pregnancy and postpartum. Thus, low levels of ANGPTL3 during pregnancy might favor lipid uptake in oxidative tissues as the main maternal energy source, while may helping to preserve glucose for use by the fetus and placenta.

15 April 2019 in Journal of the Endocrine Society
Verified
Journal Article
Open access
JCJorge Caminos
Jorge Caminos
MGMaria Garces
Maria Garces
EAEdith Angel-Müller
Edith Angel-Müller
ESElizabeth Sanchez
Elizabeth Sanchez
JPJuan Carlos Pulido-Urbano
Juan Carlos Pulido-Urbano
ARAriel Iván Ruiz-Parra
Ariel Iván Ruiz-Parra
Gestation is a diabetogenic state due to insulin resistance. Pregnant women with higher insulin resistance are at risk of developing preeclampsia and vascular dysfunction. Fasting glucose to insulin ratio (G0/I0) and Fasting Insulin Resistance Index (FIRI = (G0 x I0)/25) are surrogate indices of insulin sensitivity of the euglycemic-hyperinsulinemic clamp. The aim of this study was to determine G0/I0&nbsp;and FIRI in normal (n = 142) and preeclamptic pregnancies (n = 18), during the three periods of gestation, and three months postpartum. Also, 52 healthy non-pregnant women were studied. The study was approved by the Ethics Committee of the Faculty of Medicine and the participants provided written informed consent. A serum biochemical analysis of fasting insulin, blood glucose, total cholesterol, triglyceride and HDL cholesterol was done. G0/I0 and FIRI were calculated. Statistical analyzes were performed with R software. In healthy pregnancy, G0/I0 decreased significantly in the second (8.5 ± 4.3) and third periods (6.7 ± 3.0), compared to the first one (11.1 ± 5.7), non-pregnant women (11.3 ± 7.0) and postpartum (13.1 ± 7.9) (p<0.01). In preeclamptic patients, G0/I0 decreased significantly from the first period (7.1 ± 1.6) to the end of pregnancy (6.2 ± 4.2) (p<0.05). In these women, G0/I0 rose in the postpartum period (7.6 ± 4.4) without reaching the values of non-pregnant women (11.3 ± 7.0). The difference in the G0/I0, between healthy pregnant and preeclamptic women was due to the increase in basal insulin. A significant correlation was found between G0/I0 and QUICKI, HOMA-IR and FIRI indices, during the three gestation periods and postpartum in healthy and preeclamptic, and in non-pregnant women. In healthy pregnancy, FIRI decreased significantly (p <0.05) in the first period (27.4 ± 13.7), and increased in the third period (38.4 ± 16.1 compared with non-pregnant women 33.3 ± 16.0), and decreased significantly (p <0.05) in the postpartum (27.7 ± 17.3 (p<0.01)). In preeclamptic women, the FIRI increased significantly from the second period (47.3 ± 13.7) to the end of pregnancy (45.7 ± 21.5) (p <0.05) and in postpartum (48.5 ± 28.1), compared with non-pregnant women (33.3 ± 16.0). The FIRI was not different in the third period of gestation between healthy pregnant and preeclamptic women. The FIRI was correlated with QUICKI, HOMA-IR and G0/I0 indices during the different periods of pregnancy and postpartum, in healthy pregnant and preeclamptic women, and with the TyG and TG/HDL-c indices only in postpartum in preeclamptic women. In conclusion, these different indices of surrogate insulin resistance (G0/I0, FIRI, QUICKI, HOMA-IR, TyG and TG/HDL-c) can be used to predict insulin resistance during pregnancy. Preeclamptic women had more insulin resistance from early pregnancy and this state persists longer than in healthy pregnant women.

27 October 2025 in JCEM Case Reports
Verified
Journal Article
Open access
LBLaura Natalia Bermúdez-Silva
Laura Natalia Bermúdez-Silva
Julieth Daniela Buell AcostaJulieth Daniela Buell Acosta
Julieth Daniela Buell Acosta
LLLuz Andrea León-Cárdenas
Luz Andrea León-Cárdenas
JPJhon Jairo Peralta-Franco
Jhon Jairo Peralta-Franco
Androgen-secreting adrenal adenomas are an exceptionally rare cause of hyperandrogenism, particularly in postmenopausal women. Hirsutism is a frequent clinical manifestation and warrants a comprehensive evaluation to distinguish between ovarian and adrenal sources. We present the case of a postmenopausal woman with a history of progressive hirsutism and virilization. Biochemical evaluation revealed elevated dehydroepiandrosterone sulfate (DHEAS) and total testosterone. Pelvic lesions were ruled out but abdominopelvic tomography revealed a 41 × 30 mm left adrenal mass. The remaining hormonal profile was unremarkable. The patient underwent left adrenalectomy, with immunohistopathological analysis confirming an adrenal adenoma. Postoperatively, her androgen levels significantly decreased, accompanied by clinical improvement in hirsutism. Although the vast majority of hyperandrogenic states in postmenopausal women are secondary to ovarian pathology, adrenal etiologies must be ruled out. Androgen-producing adrenal adenomas represent a rare cause of hyperandrogenism, and this case contributes further evidence regarding the clinical and biochemical behavior of these benign lesions.